Interview with Mao-Ting Sheen, Director, Medical Review and Pharmaceutical Benefits Division, Bureau of National Health Insurance (BNHI) of Taiwan
08.07.2013
Related Interviews
Louis Cheng – CEO, Leadgene Biomedical, Taiwan
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
APAC / IFPMA's Thomas Cueni on the Value of Business Ethics for SMEs during COVID-19
Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and…
Global / Astellas CMO Bernie Zeiher: Leaving No Stone Unturned in the Quest for Patient Value
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Vaccine Nationalism / “Moral Obscenity, Public Health Catastrophe & Economic Folly”
Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time…
Latest Report
